Download This Paper
Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.
Effectiveness of Inactivated COVID-19 Vaccines Against COVID-19 Pneumonia and Severe Illness Caused by the B.1.617.2 (Delta) Variant: Evidence from an Outbreak in Guangdong, China
18 Pages Posted: 5 Aug 2021
More...Abstract
Background: Real-world evidence (RWE) of a vaccine supplements clinical trial data by providing information in populations differing from clinical trial populations, under different epidemiological situations, on alternative outcomes, or against different pathogen lineages. To date, RWE on inactivated COVID-19 vaccines against the highly transmissible SARS-CoV-2 B.1.617.2 (Delta) variant is limited, leaving an important gap in the evidence base of inactivated COVID-19 vaccines for use by immunization programs.
Methods: Between May and June 2021, an outbreak of the B.1.617.2 variant was discovered and traced in Guangdong, China. Before this outbreak, Guangdong province had started mass vaccination using inactivated vaccines approved by China’s regulator for use in adults. Using surveillance and vaccination data from the outbreak, we assessed the real-world effectiveness of inactivated vaccines against pneumonia and severe illness caused by the B.1.617.2 variant. We enrolled 10813 subjects who were close contacts of laboratory-confirmed cases, categorizing them as an unvaccinated group, a partially vaccinated (1-dose) group, and a fully vaccinated (2-dose) group. We estimated relative risk (RR) and vaccine effectiveness (VE) of the vaccinated groups in relation to the unvaccinated group.
Findings: Unadjusted and adjusted VE of full vaccination against pneumonia were 77·7% (95% CI 45·1–90·9) and 69·5% (95% CI 42·8–96·3), respectively. Full vaccination was 100% effective against severe illness. Unadjusted and adjusted VE of partial vaccination against pneumonia were 1·4% (95% CI -79·7–45·9) and 8·4% (95% CI -47·6–64·4). Interpretation Full vaccination with inactivated vaccines is effective against pneumonia, severe, and critical illness caused by the B.1.617.2 variant. Effort should be placed to ensure full vaccination of target populations.
Funding: National Natural Science Foundation of China and Key-Area Research and Development Program of Guangdong.
Declaration of Interest: None to declare.
Ethical Approval: This study was approved by the institutional ethics committee of the Guangdong Provincial Center for Disease Control and Prevention (GDCDC). Data in the study were collected per administrative requirements of disease control and surveillance, and were anonymized for analysis. Participants were informed about the requirements of disease surveillance and provided oral consents.
Suggested Citation: Suggested Citation